Patients
Sites
Sponsors
About Us
News
Sites access
Onco access
EN
Last updated 23 days ago
Share
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
40 patients around the world
Available in
Brazil
Federal University of São Paulo
40
Patients around the world
This study is for people with
Hiv
Requirements for the patient
To 50 Years
Male
Medical requirements
Inclusion criteria
Confirmed HIV infection.
Antiretroviral naive.
HIV Viral load > 1.000.
CD4+ T cell counts >350 cells/mm3.
Body weight > 50 Kg.
Signed informed consent form.
Exclusion criteria
BMI < 18.5 kg/m2 at screening.
Coinfection with HBV (HBsAg +) or HCV.
Any significant acute illness within one week before the first visit.
Use of any immunomodulatory therapy (including interferon), systemic steroids, or systemic chemotherapy within four weeks before screening.
Active malignancy or malignancy in follow-up.
Changes in safety tests: neutrophil count < 1,000 u/L; Hb < 9.0 gm/dl; platelet count < 75,000 u/L; creatinine > 1.5 mg/dl, direct bilirubin > 85 μmol/L, AST or ALT > 2.5 X UNL.
Potential allergy or hypersensitivity to the components of the Gammora® formulation.
Participation in another clinical trial within 12 months before screening.
Any medical condition that makes the participant unsuitable for the study or increases the risk of participation at the investigator's discretion.
See details
Contact us
Contact us
Sponsor
Federal University of São Paulo
Study type
Interventional
Conditions
Hiv
Requirements
To 50 Years
Male
Unique study ID
clinicaltrials.gov
NCT06799650
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent